Bélanger L G, Charbonneau M, Lavallée J P, Lenis J, Ouellet A C
Can J Cardiol. 1986 Jul-Aug;2(4):212-7.
The calcium antagonists are presently accepted as the treatment of choice for vasospastic angina. They are accepted by some as a good second choice therapy in the treatment of stable angina pectoris, while by others as an excellent first choice in its treatment. When introduced to the North American market, warning was given of the risk of left ventricular failure and/or atrioventricular block from their combination with beta-blockers. Perhaps now a deeper knowledge of their hemodynamic and electrophysiologic properties allows us to conceptualize potent and safe anti-anginal associations by use, in specific patients, of differing combinations. Thus we must learn to use with care and flair this new form of treatment which offers our severely afflicted patients much greater symptomatic relief.
钙拮抗剂目前被公认为是变异性心绞痛的首选治疗药物。一些人认为它们是稳定型心绞痛治疗的良好二线治疗药物，而另一些人则认为它们是治疗稳定型心绞痛的极佳一线药物。当引入北美市场时，曾有人警告说，它们与β受体阻滞剂联合使用会有左心室衰竭和/或房室传导阻滞的风险。也许现在对它们的血流动力学和电生理特性有了更深入的了解，使我们能够通过在特定患者中使用不同的组合来构思有效且安全的抗心绞痛联合用药方案。因此，我们必须学会谨慎而巧妙地使用这种新的治疗方式，它能为我们病情严重的患者带来更大的症状缓解。
